Glucose intolerance with atypical antipsychotics.

Drug Epidemiology Unit, Medical Products Agency, Uppsala, Sweden.
Drug Safety (Impact Factor: 2.62). 02/2002; 25(15):1107-16. DOI: 10.2165/00002018-200225150-00005
Source: PubMed

ABSTRACT Previous studies have suggested that the atypical antipsychotics clozapine and olanzapine may be associated with an increased risk of glucose intolerance and diabetes mellitus. Early studies have also suggested an association between use of conventional antipsychotics and the development of glucose intolerance.
To examine quantitatively the association between glucose intolerance including diabetes mellitus and the use of the atypical antipsychotics clozapine, olanzapine or risperidone, and to identify possible risk factors for the development of glucose intolerance during treatment with these drugs.
All reports suggestive of glucose intolerance for clozapine, olanzapine and risperidone were identified in the WHO database for adverse drug reactions. In the analyses of possible risk factors for glucose intolerance all other reports of adverse drug reactions for clozapine, olanzapine and risperidone were used as reference. Using the Bayesian Confidence Propagation Neural Network method, the strengths of the associations over time between glucose intolerance and the use of these drugs were analysed. For comparison, the strengths of the associations between glucose intolerance and the use of the conventional antipsychotics haloperidol and chlorpromazine were also analysed.
Clozapine, olanzapine and risperidone were significantly associated with glucose intolerance. In contrast, chlorpromazine and haloperidol were not associated with glucose intolerance. For clozapine, olanzapine and risperidone grouped together, the following potential risk factors for glucose intolerance were identified: an underlying diabetic condition (odds ratio [OR] 10.22, 95% CI 8.20-12.73), an increase in weight (OR 2.36, 95% CI 1.76-3.17), male gender (OR 1.27, 95% CI 1.11-1.47), and concomitant use of valproic acid (OR 1.97, 95% CI 1.61-2.40), selective serotonin reuptake inhibitors (OR 1.63, 95% CI 1.33-1.99) or buspirone (OR 2.24, 95% CI 1.33-3.77).
Treatment with clozapine, olanzapine or risperidone appears to be associated with an increased risk of glucose intolerance.

  • [Show abstract] [Hide abstract]
    ABSTRACT: The prevalence of autism spectrumdisorders (ASDs) appears to have increased by nearly a quarter from 2006 to 2008.Much of this growth is probably because of improved awareness, broader definitions, and better diagnosis, but it is possible that the true number of individuals with autism may also be increasing. Children with ASDs and their parents need anticipatory guidance and ongoing assistance from the entire medical and behavioral treatment team. Conventional medical nutrition therapy, such as anthropometric assessment and optimizing feeding strategies, is essential for the nutritional care of children with ASDs. Complementary and alternative therapies, including elimination diets and dietary supplements, are increasingly popular, even though the evidence for their efficacy is still limited.
    Nutrition Today 01/2014; 49(4):196-206. DOI:10.1097/NT.0000000000000037
  • [Show abstract] [Hide abstract]
    ABSTRACT: The incidence of type 2 diabetes mellitus is increasing rapidly, as are the associated co-morbidities. Consequently, it has become necessary for a diabetic patient to take multiple medications at the same time to delay progression of the disease. This can put patients at an increased risk of moderate to severe drug interactions, which may threaten patients' life or may deteriorate the quality of their life. Hence, managing drug-drug interactions is the cornerstone of anti-diabetic therapy. Most of the clinically important drug-drug interactions of anti-diabetic agents are related to their metabolic pathways, but drugs that compete for renal excretion or impair renal status can also play an important role. In this review, we have examined the clinical implications and underlying mechanisms of drugs that are likely to alter the pharmacologic response of or cause adverse events with antidiabetic drugs, and we have outlined safe and efficacious treatment modalities.
    Drug Safety 09/2014; 37(11). DOI:10.1007/s40264-014-0223-2 · 2.62 Impact Factor
  • Source
    01/2014; 17(2):54-57. DOI:10.5455/bmmr.43258


Available from
Mar 19, 2015